Stockreport

Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant S...

Verastem, Inc.  (VSTM) 
Last verastem, inc. earnings: 10/29 04:17 pm Check Earnings Report
US:NASDAQ Investor Relations: verastem.com
PDF First two monotherapy dose levels (400 mg QD and 600 mg QD) cleared, with no dose-limiting toxicities reportedPromising anti-tumor activity observed in patients with var [Read more]